|
[1]
|
Windpessl M, Heine GH, Becker SL, Scheuer AL, Sester M, Kronbichler A. The impact of immunosuppression and chronic kidney disease on immunogenicity of COVID-19 vaccines. Dtsch Med Wochenschr 2021;146(19):1277 − 82. https://doi.org/10.1055/A-1550-7288CrossRef
|
|
[2]
|
Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination guidelines for patients with immune-mediated disorders taking immunosuppressive therapies: executive summary. J Rheumatol 2019;46(7):751 − 4. https://doi.org/10.3899/jrheum.180784CrossRef
|
|
[3]
|
Habib MB, Ali K, Rahhal A, Obeidat I, Altermanini M, Sawaf B, et al. Determinants of vaccine adherence among non-dialysis chronic kidney disease patients in Qatar. Qatar Med J 2024;2023(4):33. https://doi.org/10.5339/qmj.2023.33CrossRef
|
|
[4]
|
Krueger KM, Ison MG, Ghossein C. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am J Kidney Dis 2020;75(3):417 − 25. https://doi.org/10.1053/j.ajkd.2019.06.014CrossRef
|
|
[5]
|
Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). Chin J Clin Infect Dis 2022;15(6):401 − 27. https://doi.org/10.3760/cma.j.issn.1674-2397.2022.06.001CrossRef
|
|
[6]
|
Zhang X, Wang J, Chen X, Yu ML, Yu SB, Sun YY, et al. Short-term immunogenicity of standard and accelerated hepatitis B virus vaccination schedules in healthy adults: a comparative field study in China. Biosci Rep 2018;38(5):BSR20180846. https://doi.org/10.1042/BSR20180846CrossRef
|
|
[7]
|
Wang J, Liu CH, Ma YJ, Zhu X, Luo LR, Ji YL, et al. Two-year immune effect differences between the 0-1-2-month and 0-1-6-month HBV vaccination schedule in adults. BMC Infect Dis 2022;22(1):159. https://doi.org/10.1186/s12879-022-07151-6CrossRef
|
|
[8]
|
Hwang LY, Grimes CZ, Tran TQ, Clark A, Xia P, Lai DJ, et al. Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial. J Infect Dis 2010;202(10):1500 − 9. https://doi.org/10.1086/656776CrossRef
|
|
[9]
|
Vargas JI, Jensen D, Martínez F, Sarmiento V, Peirano F, Acuña P, et al. Comparative efficacy of a high-dose vs standard-dose hepatitis B revaccination schedule among patients with HIV: a randomized clinical trial. JAMA Netw Open 2021;4(8):e2120929. https://doi.org/10.1001/jamanetworkopen.2021.20929CrossRef
|
|
[10]
|
Feng YL, Han YJ, Yao T, Wang JM, Liu HT, Guo HP, et al. Immunogenicity and influencing factors of hepatitis B vaccination based on different vaccination schedules among chronic kidney disease patients. Chin J Epidemiol 2022;43(2):241 − 7. https://doi.org/10.3760/cma.j.cn112338-20210807-00618CrossRef
|